Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.967
+0.006 (0.59%)
Nov 21, 2024, 3:54 PM EST - Market closed
Prelude Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 29.56 | 28.88 | 30.65 | 26.96 | 10.59 | 3.83 | |
| Research & Development | 116.71 | 103.39 | 92.89 | 86.78 | 48.18 | 24.28 | |
| Operating Expenses | 146.26 | 132.28 | 123.54 | 113.74 | 58.76 | 28.11 | |
| Operating Income | -143.26 | -132.28 | -123.54 | -113.74 | -58.76 | -28.11 | |
| Other Non Operating Income (Expenses) | 11.75 | 10.45 | 8.1 | 2.04 | 1.83 | 0.54 | |
| Pretax Income | -131.52 | -121.83 | -115.44 | -111.69 | -56.93 | -27.57 | |
| Net Income | -131.52 | -121.83 | -115.44 | -111.69 | -56.93 | -27.57 | |
| Net Income to Common | -131.52 | -121.83 | -115.44 | -111.69 | -56.93 | -27.57 | |
| Shares Outstanding (Basic) | 74 | 60 | 47 | 46 | 12 | 2 | |
| Shares Outstanding (Diluted) | 74 | 60 | 47 | 46 | 12 | 2 | |
| Shares Change (YoY) | 35.27% | 27.41% | 2.87% | 269.03% | 647.86% | 18.93% | |
| EPS (Basic) | -1.77 | -2.02 | -2.44 | -2.43 | -4.56 | -16.52 | |
| EPS (Diluted) | -1.77 | -2.02 | -2.44 | -2.43 | -4.56 | -16.52 | |
| Free Cash Flow | -107.56 | -110.58 | -86.75 | -85.85 | -46.8 | -26.45 | |
| Free Cash Flow Per Share | -1.45 | -1.83 | -1.83 | -1.86 | -3.75 | -15.85 | |
| EBITDA | -141.65 | -131.11 | -122.22 | -112.82 | -58.22 | -27.73 | |
| D&A For EBITDA | 1.61 | 1.17 | 1.32 | 0.92 | 0.54 | 0.38 | |
| EBIT | -143.26 | -132.28 | -123.54 | -113.74 | -58.76 | -28.11 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.